To achieve capital growth whilst maintaining a reasonable yield through a diversified Investments largely in equity markets with a bias towards UK and international equities, fixed income securities issued by governments, corporations and bank deposits.
Name | % Net Assets |
---|---|
BP | 6.3% |
HSBC | 5.4% |
GlaxoSmithKline | 4.1% |
Standard Chartered | 4.0% |
BP | 3.6% |
Unilever | 3.5% |
Imperial Tobacco | 3.5% |
BG | 3.2% |
BHP Billiton | 3.0% |
Anglo American | 2.8% |
Key | % Net Assets |
---|---|
BP | 6.3% |
HSBC | 5.4% |
GlaxoSmithKline | 4.1% |
Standard Chartered | 4.0% |
Other | 80.2% |
Date | 25-Apr-2024 |
---|---|
NAV | 201.10p |
Currency | GBP |
Change | -0.20p |
% | -0.10% |
YTD change | 4.90p |
YTD % | 2.50% |
Fund Inception | 01/06/1999 |
---|---|
Fund Manager | Alan Custis / Gabrielle Boyle / Ian Smart and teams |
TER | 0.95 (31-Mar-2014) |
Minimum Investment | |
---|---|
Initial | £200000 |
Additional | £500 |
Savings | £75 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.75% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.07 |
You are here: research